Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling

Tumor Biology

Volumn 37, Issue 8, 2016, Pages 11007-11015

  Guo, Lili ^a,b   Zhou, Bo ^a   Liu, Zhengqing ^b   Xu, Ying ^a   Lu, Hao ^a   Xia, Meng ^a   Guo, Ensong ^a   Shan, Wanying ^a   Chen, Gang ^a   Wang, Changyu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

Drug resistance; GLS1; Glutaminase1; Metabolic reprogramming; Ovarian cancer

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; 2 OXOGLUTARIC ACID; CB 839; ENZYME INHIBITOR; GLUTAMINASE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZENEACETAMIDE DERIVATIVE; CB-839; GLS1 PROTEIN, HUMAN; GLUTAMINE; INDOLE DERIVATIVE; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; STAT3 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; THIADIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; DOWN REGULATION; ENZYME INHIBITION; FLOW CYTOMETRY; GENETIC TRANSFECTION; GLUTAMINOLYSIS; HUMAN; HUMAN CELL; LYSIS; OVARIAN CANCER CELL LINE; OVARY CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SENSITIZATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE SILENCING; METABOLISM; OVARY TUMOR; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENEACETAMIDES; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; GLUTAMINASE; GLUTAMINE; HUMANS; INDOLES; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PURINES; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; THIADIAZOLES; TOR SERINE-THREONINE KINASES;

EID: 84958745727     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-4984-3     Document Type: Article

References (36)

1. Mabuchi S, Kuroda H, Takahashi R, Sasano T. The pi3k/akt/mtor pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 2015;137(1):173–9.
2. Mabuchi S, Hisamatsu T, Kimura T. Targeting mtor signaling pathway in ovarian cancer. Curr Med Chem. 2011;18(19):2960–8.
3. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, et al. Akt and mtor phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004;23(34):5853–7.
4. Ghadimi MP, Lopez G, Torres KE, Belousov R, Young ED, Liu J, et al. Targeting the pi3k/mtor axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2012;11(8):1758–69.
5. Workman P, Clarke PA, Raynaud FI, van Montfort RL. Drugging the pi3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 2010;70(6):2146–57.
6. Schenone S, Brullo C, Musumeci F, Radi M, Botta M. Atp-competitive inhibitors of mtor: an update. Curr Med Chem. 2011;18(20):2995–3014.
7. Chiarini F, Evangelisti C, McCubrey JA, Martelli AM. Current treatment strategies for inhibiting mtor in cancer. Trends Pharmacol Sci. 2015;36(2):124–35.
8. Brown KK, Toker A. The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000Prime Rep. 2015;7:13.
9. Li J, Kim SG, Blenis J. Rapamycin: one drug, many effects. Cell Metab. 2014;19(3):373–9.
10. Husseinzadeh N, Husseinzadeh HD. Mtor inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review. Gynecol Oncol. 2014;133(2):375–81.
11. Wander SA, Hennessy BT, Slingerland JM. Next-generation mtor inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest. 2011;121(4):1231–41.
12. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, et al. Active-site inhibitors of mtor target rapamycin-resistant outputs of mtorc1 and mtorc2. PLoS Biol. 2009;7(2):e38. doi:10.1371/journal.pbio.1000038.
13. Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015;34(1):111.
14. Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol. 2014;10:728.
15. Yu D, Shi X, Meng G, Chen J, Yan C, Jiang Y, et al. Kidney-type glutaminase (gls1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma. Oncotarget. 2015;6(10):7619–31.
16. Koo JS, Yoon JS. Expression of metabolism-related proteins in lacrimal gland adenoid cystic carcinoma. Am J Clin Pathol. 2015;143(4):584–92.
17. Pan T, Gao L, Wu G, Shen G, Xie S, Wen H, et al. Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer. Biochem Biophys Res Commun. 2015;456(1):452–8.
18. Kim MJ, Kim DH, Jung WH, Koo JS. Expression of metabolism-related proteins in triple-negative breast cancer. Int J Clin Exp Pathol. 2013;7(1):301–12.
19. Huang F, Zhang Q, Ma H, Lv Q, Zhang T. Expression of glutaminase is upregulated in colorectal cancer and of clinical significance. Int J Clin Exp Pathol. 2014;7(3):1093–100.
20. van den Heuvel AP, Jing J, Wooster RF, Bachman KE. Analysis of glutamine dependency in non-small cell lung cancer: Gls1 splice variant gac is essential for cancer cell growth. Cancer Biol Ther. 2012;13(12):1185–94.
21. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013;4:e532. doi:10.1038/cddis.2013.60.
22. Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, et al. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with bcl-2 inhibition. Blood. 2015;126(11):1346–56.
23. Jewell JL, Kim YC, Russell RC, Yu FX, Park HW, Plouffe SW, et al. Metabolism. Differential regulation of mtorc1 by leucine and glutamine. Science. 2015;347(6218):194–8.
24. Csibi A, Fendt SM, Li C, Poulogiannis G, Choo AY, Chapski DJ, et al. The mtorc1 pathway stimulates glutamine metabolism and cell proliferation by repressing sirt4. Cell. 2013;153(4):840–54.
25. Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, et al. Compensatory glutamine metabolism promotes glioblastoma resistance to mtor inhibitor treatment. J Clin Invest. 2015;125(4):1591–602.
26. Yuan L, Sheng X, Willson AK, Roque DR, Stine JE, Guo H, et al. Glutamine promotes ovarian cancer cell proliferation through the mtor/s6 pathway. Endocr Relat Cancer. 2015;22(4):577–91.
27. Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the point of inhibition: a comparative review of pi3k/akt/mtor pathway inhibitors. Mol Cancer Ther. 2014;13(5):1021–31.
28. Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, et al. Inhibition of pi3k/mtor leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell. 2012;21(2):227–39.
29. You S, Li R, Park D, Xie M, Sica GL, Cao Y, et al. Disruption of stat3 by niclosamide reverses radioresistance of human lung cancer. Mol Cancer Ther. 2014;13(3):606–16. doi:10.1158/1535-7163.MCT-13-0608.
30. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008;13(6):472–82.
31. Gupta V, Wellen KE, Mazurek S, Bamezai RN. Pyruvate kinase m2: regulatory circuits and potential for therapeutic intervention. Curr Pharm Des. 2014;20(15):2595–606.
32. Guo W, Zhang Y, Chen T, Wang Y, Xue J, Zhang Y, et al. Efficacy of rnai targeting of pyruvate kinase m2 combined with cisplatin in a lung cancer model. J Cancer Res Clin Oncol. 2011;137(1):65–72.
33. Dwarakanath B, Jain V. Targeting glucose metabolism with 2-deoxy-d-glucose for improving cancer therapy. Future Oncol. 2009;5(5):581–5.
34. Pradelli LA, Beneteau M, Chauvin C, Jacquin MA, Marchetti S, Munoz-Pinedo C, et al. Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by amp kinase activation leading to mcl-1 block in translation. Oncogene. 2010;29(11):1641–52.
35. Chakrabarti G, Moore ZR, Luo X, Ilcheva M, Ali A, Padanad M, et al. Targeting glutamine metabolism sensitizes pancreatic cancer to parp-driven metabolic catastrophe induced by ss-lapachone. Cancer Metab. 2015;3:12.
36. Hernandez-Davies JE, Tran TQ, Reid MA, Rosales KR, Lowman XH, Pan M, et al. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. J Transl Med. 2015;13:210. doi:10.1186/s12967-015-0581-2.